Ebola Vaccine Gets Department of Defense Funding

271

GeoVax Receives Ebola Vaccine Patent

https://www.ebolaoutbreakmap.com/listings/ebola-vaccine/

GeoVax has demonstrated that a single intramuscular (IM) dose of its ebola vaccine provided 100% protection in rhesus macaques monkeys injected with a lethal dose of Ebola virus (EBOV). This is the first report that a replication-deficient MVA vector can confer full protection against a lethal EBOV challenge after a single-dose vaccination in macaques. GEO-EM01 is based on the Company’s novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated. VLPs mimic a natural infection, triggering the body to produce a robust and durable immune response with both antibodies and T cells.

In addition to its Ebola vaccine GeoVax is also developing preventive vaccines for other hemorrhagic fever viruses highly lethal to humans. In July 2021, the Company announced results of preclinical efficacy studies of its ebola vaccine in which a single dose of the vaccine protected 100% of animals challenged with a lethal dose of SUDV. This is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose. This work was conducted in collaboration with researchers at the University of Texas Medical Branch (UTMB). Separately, GeoVax is leading a multi-party collaboration for the development of its SUDV and Marburg virus (MARV) vaccine candidates. The collaboration, between GeoVax, researchers at UTMB and Battelle Memorial Institute, utilizes the suite of preclinical services from NIAID. Under the collaboration, GeoVax’s SUDV and MARV vaccine candidates are being tested for immunogenicity and efficacy in the benchmark nonhuman primate model. Additionally, GeoVax’s vaccine against Lassa Fever virus (LASV) is progressing in preclinical studies with funding support from the U.S. Department of Defense.

David Dodd, GeoVax President and CEO, commented, “While our corporate focus and development priorities continue to be our COVID-19 vaccine and cancer immunotherapy programs, developing vaccines against lethal hemorrhagic fever viruses is also of interest and under consideration as part of our longer-term focus.  This patent allowance adds to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, which now stands at over 70 granted or pending patent applications spread over 20 patent families.”

______________________________________________________

Guest Posting

If you wish to write and/or publish an article on Operation Disclosure all you need to do is send your entry to UniversalOm432Hz@gmail.com applying these following rules.

The subject of your email entry should be: “Entry Post | (Title of your post) | Operation Disclosure”

– Must be in text format
– Proper Grammar
– No foul language
– Your signature/name/username at the top
______________________________________________________

Newsletter

If you wish to receive the daily Operation Disclosure Newsletter, you can subscribe via the PayPal “Subscribe” button located on the site.
______________________________________________________

Our mission at Operation Disclosure is to bring you important news events and raw intel from various sources focused on exposing the Deep State/Cabal and their downfall. We are also focused on disclosing our lost ancient origins and extraterrestrial contact.

Disclaimer: All articles, videos, and images posted on Operation Disclosure were submitted by readers and/or handpicked by the site itself for informational and/or entertainment purposes. All statements, claims, views and opinions that appear on this site are always presented as unverified and should be discerned by the reader. We do not endorse any opinions expressed on this website and we do not support, represent or guarantee the completeness, truthfulness, accuracy, or reliability of any content posted on this website.

Copyright © 2021 Operation Disclosure